"
Team:Freiburg/Project
From 2012.igem.org
(Difference between revisions)
| Line 6: | Line 6: | ||
{| style="color:#4F8DDE;background-color:#ffffff;" cellpadding="5" cellspacing="2" border="0" bordercolor="#fff" width="100%" align="left" | {| style="color:#4F8DDE;background-color:#ffffff;" cellpadding="5" cellspacing="2" border="0" bordercolor="#fff" width="100%" align="left" | ||
!align="center"|[[Team:Freiburg|<span style="color:#4F8DDE;">Home</span>]] | !align="center"|[[Team:Freiburg|<span style="color:#4F8DDE;">Home</span>]] | ||
| - | !align="center"|[[Team:Freiburg/Team|<span style="color:# | + | !align="center"|[[Team:Freiburg/Team|<span style="color:#4F8DDE;">Team</span>]] |
!align="center"|[https://igem.org/Team.cgi?year=2012&team_name=Freiburg<span style="color:#4F8DDE;">Official Team Profile</span>] | !align="center"|[https://igem.org/Team.cgi?year=2012&team_name=Freiburg<span style="color:#4F8DDE;">Official Team Profile</span>] | ||
| - | !align="center"|[[Team:Freiburg/Project|<span style="color:# | + | !align="center"|[[Team:Freiburg/Project|<span style="color:#4169E1;">Project</span>]] |
!align="center"|[[Team:Freiburg/Parts|<span style="color:#4F8DDE;">Parts Submitted to the Registry</span>]] | !align="center"|[[Team:Freiburg/Parts|<span style="color:#4F8DDE;">Parts Submitted to the Registry</span>]] | ||
!align="center"|[[Team:Freiburg/Modeling|<span style="color:#4F8DDE;">Modeling</span>]] | !align="center"|[[Team:Freiburg/Modeling|<span style="color:#4F8DDE;">Modeling</span>]] | ||
| Line 20: | Line 20: | ||
| + | |||
| + | =<span style="color:#2244AA"> Project = | ||
| Line 25: | Line 27: | ||
Since April 2012, we are working in the field of so called TAL effectors in our lab. TAL effectors are molecular machines that are fused to DNA binding proteins in order to restrict their acticvity to specific loci in a genome. In particular, we develop a strategy to cheaply create novel TAL effectors in an extremely short period of time. This new method will enable us to test numerous novel effectors in human cells and to assess their therapeutic potential for genetic diseases, epigenetic alterations and cancer. | Since April 2012, we are working in the field of so called TAL effectors in our lab. TAL effectors are molecular machines that are fused to DNA binding proteins in order to restrict their acticvity to specific loci in a genome. In particular, we develop a strategy to cheaply create novel TAL effectors in an extremely short period of time. This new method will enable us to test numerous novel effectors in human cells and to assess their therapeutic potential for genetic diseases, epigenetic alterations and cancer. | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
Revision as of 09:32, 8 June 2012
|
| Home | Team | Official Team Profile | Project | Parts Submitted to the Registry | Modeling | Notebook | Safety | Attributions |
|---|
|
Project
Overall project
Since April 2012, we are working in the field of so called TAL effectors in our lab. TAL effectors are molecular machines that are fused to DNA binding proteins in order to restrict their acticvity to specific loci in a genome. In particular, we develop a strategy to cheaply create novel TAL effectors in an extremely short period of time. This new method will enable us to test numerous novel effectors in human cells and to assess their therapeutic potential for genetic diseases, epigenetic alterations and cancer.
Promote Synthetic Biology
|
|
